CalciMedica expects Auxora Phase 1b PAH trial data and CM5480 IND submission in mid-2027
Company expects current cash to fund operations into the second half of 2027
Initiation of Phase 2b Auxora trial in acute pancreatitis subject to additional financing
Overview
Biopharmaceutical developer's Q2 net loss widened yr/yr
Company completed private placement financing of up to $49 mln to advance pulmonary hypertension program
Cash and equivalents of $18.6 mln expected to fund operations into H2 2027
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for CalciMedica Inc is $10.50, about 1,493.3% above its August 10 closing price of $0.66
Result drivers and key details
Lower R&D and G&A expenses - Co said declines in research and development and general and administrative expenses were due to reduced preclinical and clinical trial activities, as well as lower personnel and consultant costs
CALC•
